Positive trial results for Biogen Idec's MS drug BG-12

21 September 2012

US biotech firm Biogen Idec (Nasdaq: BIIB) says that data from the Phase III DEFINE and CONFIRM studies show that BG-12 (dimethyl fumarate) 240mg, administered twice daily (BID) or three times daily (TID), demonstrated significant and clinically meaningful reductions in multiple sclerosis relapses and brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS) compared to placebo, as well as showing benefit in slowing the progression of the disease.

The results of the two pivotal clinical trials were published in the New England Journal of Medicine (September 20 issue). Dimethyl fumarate is currently under review by regulatory authorities in the USA, European Union, Australia, Canada and Switzerland.

Peak sales potential of $3 billion projected

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK